Terumo (OTCMKTS:TRUMY) Shares Gap Down – Should You Sell?

Posted by Brenda Bartman on Oct 10th, 2026

Terumo Corp. (OTCMKTS:TRUMY – Get Free Report)’s stock price gapped down prior to trading on Thursday. The stock had previously closed at $14.66, but opened at $13.92. Terumo shares last traded at $13.92, with a volume of 9,557 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Nomura upgraded Terumo from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Terumo has an average rating of “Buy”.

View Our Latest Stock Analysis on Terumo

Terumo Trading Up 7.7%

The company’s fifty day simple moving average is $15.13 and its two-hundred day simple moving average is $14.19. The company has a market capitalization of $21.06 billion, a price-to-earnings ratio of 20.11 and a beta of 0.77. The company has a quick ratio of 1.37, a current ratio of 2.19 and a debt-to-equity ratio of 0.13.

Terumo (OTCMKTS:TRUMY – Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.13. Terumo had a net margin of 13.83% and a return on equity of 10.44%. The company had revenue of $1.97 billion during the quarter, compared to analyst estimates of $1.84 billion. Research analysts forecast that Terumo Corp. will post 0.86 earnings per share for the current fiscal year.

Terumo Company Profile

(Get Free Report)

Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells products used in hospitals, clinics and other healthcare settings. Founded in 1921 by a group of Japanese medical doctors, the company initially produced clinical thermometers and has since expanded into a global provider of medical devices and related services.

Terumo’s principal businesses include cardiac and vascular products, blood and cell technologies, and general hospital solutions.